Effective-constituent compatibility-based analysis of Bufei Yishen formula, a traditional herbal compound as an effective treatment for chronic obstructive pulmonary disease
Effective-constituent compatibility-based analysis of Bufei Yishen formula, a traditional herbal compound as an effective treatment for chronic obstructive pulmonary disease
复制标题
DOI：
10.1016/j.joim.2020.04.004
复制
发表时间：
2020-07-01
影响因子：
4.8
通讯作者：
Xie, Yang
中科院分区：
文献类型：
--
作者：
Li, Jian-sheng;Liu, Xue-fang;Xie, Yang
目的：从补肺益肾方(BYF)中鉴定出与补肺益肾方具有潜在生物活性等效性的有效成分。方法：采用4种细胞模型对补肺益肾方的有效成分进行鉴定，并根据中医理论将其分为补肺益肾1组、补肾补肾2组、化痰3组、活血4组。以药理活性为指标，采用正交法和组合法确定各组有效成分的最佳配比及“1~4组”的最佳配比。我们还在慢性阻塞性肺疾病(COPD)大鼠模型上全面评估了BYF和BYF I的ECC之间的生物活性等效性。结果：我们从BYF中鉴定出12种活性成分。组1、组2、组5、组4的化学成分数分别为3、2、5、2。我们确定了每组中有效选民的最佳比例。第1组人参总皂苷：黄芪多糖：黄芪甲苷IV的比例为9：5：2；第2组的淫羊藿苷：五味子乙素的比例为100：12.5。第3组nobiletin:hesperidin:peimine:peiminine:kaempferol比例为4：30：6.2 5：0：0。4组中，丹皮苷与丹皮酚的比例为4：1。采用正交法确定了白藜芦醇提取液中第1组、第2组、第3组、第4组的最佳配比为：人参总皂苷：黄芪多糖：黄芪甲苷：淫羊藿苷：五味子乙素：五味子乙素：去甲肾上腺素：橙皮苷：贝母素：牡丹苷：丹皮酚为22.5：12.5：5：100：12.5：4：30：6.25：25：6.25。综合评价结果表明，BYF-I的ECC与原BYF具有生物活性等效性。结论：以中药方剂的ECC为基础，将BYF的有效成分按一定比例组合为BYF-I的ECC，其治疗COPD大鼠的效果与BYF相同。(C)2020年上海长海医院。爱思唯尔出版，版权所有。
Objective: Critical effective constituents were identified from Bufei Yishen formula (BYF), a traditional herbal compound and combined as effective-constituent compatibility (ECC) of BYF I, which may have potential bioactive equivalence to BYF.Methods: The active constituents of BYF were identified using four cellular models and categorised into Groups 1 (Bufeiqi), 2 (Bushen), 3 (Huatan) and 4 (Huoxue) according to Chinese medicinal theory. An orthogonal design and a combination method were used to determine the optimal ratios of effective constituents in each group and the ratios of "Groups 1 to 4" according to their pharmacological activity. We also comprehensively assessed bioactive equivalence between the BYF and the ECC of BYF I in a rat model of chronic obstructive pulmonary disease (COPD).Results: We identified 12 active constituents in BYF. The numbers of constituents in Groups 1 to 4 were 3, 2, 5 and 2, respectively. We identified the optimal ratios of effective constituentswithin each group. In Group 1, total ginsenosides:Astragalus polysaccharide:astragaloside IV ratio was 9:5:2. In Group 2, icariin:schisandrin B ratio was 100:12.5. In Group 3, nobiletin:hesperidin:peimine:peiminine:kaempferol ratio was 4:30:6.25:0:0. In Group 4, paeoniflorin:paeonol ratio was 4:1. An orthogonal design was then used to establish the optimal ratios of Group 1, Group 2, Group 3 and Group 4 in ECC of BYF I. The ratio for total ginsenosides:Astragalus polysaccharide:astragaloside IV:icariin:schisandrin B:nobiletin:hesperidin:peimine: paeoniflorin:paeonol was determined to be 22.5:12.5:5:100:12.5:4:30:6.25:25:6.25. A comprehensive evaluation confirmed that ECC of BYF I presented with bioactive equivalence to the original BYF.Conclusion: Based on the ECC of traditional Chinese medicine formula method, the effective constituents of BYF were identified and combined in a fixed ratio as ECC of BYF I that was as effective as BYF itself in treating rats with COPD. (C) 2020 Shanghai Changhai Hospital. Published by Elsevier B.V. All rights reserved.